BioAge Labs (BIOA) COO receives new stock option awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Morgen Eric reported acquisition or exercise transactions in this Form 4 filing.

BioAge Labs, Inc. director and Chief Operating Officer Morgen Eric reported receiving new stock option awards. One option grant covers 110,000 shares held directly, and a separate option grant covers 12,500 shares held indirectly by the reporting person's spouse.

Each option vests in equal monthly installments of 1/48 of the total award, with the first tranche vested on February 1, 2026 and additional tranches vesting on each monthly anniversary. Vesting depends on continued service to BioAge Labs on each vesting date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Morgen Eric

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	110,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	12,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 110,000 shares (Direct); Stock Option (Right to Buy) — 12,500 shares (Indirect, By Spouse)

Footnotes (1)

The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date. Represents an employee stock option directly held by the reporting person's spouse.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/19/2026 - 04:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morgen Eric

(Last)

(First)

(Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE

94608

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$19.63	02/17/2026		A		110,000		⁽¹⁾	02/16/2036	Common Stock	110,000	$0	110,000	D
Stock Option (Right to Buy)	$19.63	02/17/2026		A		12,500		⁽²⁾	02/16/2036	Common Stock	12,500	$0	12,500	I	By Spouse⁽³⁾

Explanation of Responses:

1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

2. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date.

3. Represents an employee stock option directly held by the reporting person's spouse.

	/s/ Dov A. Goldstein as attorney-in-fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BioAge Labs (BIOA) report for Morgen Eric?

BioAge Labs reported that Chief Operating Officer and director Morgen Eric received grants of stock options. One option covers 110,000 shares held directly, while another covers 12,500 shares held indirectly through the reporting person’s spouse, reflecting equity-based executive compensation.

How many BioAge Labs (BIOA) shares are covered by the new stock options?

The reported stock option awards cover 110,000 shares held directly by Morgen Eric and 12,500 shares held indirectly through the reporting person’s spouse. These derivative securities represent rights to acquire common stock rather than immediate ownership of BioAge Labs shares.

What is the vesting schedule for Morgen Eric’s BioAge Labs (BIOA) stock options?

Each option vests as to 1/48 of the total award every month. The first tranche vested on February 1, 2026, with subsequent tranches vesting on each monthly anniversary, conditioned on the holder’s continued service to BioAge Labs on each vesting date.

How are the spouse-held BioAge Labs (BIOA) stock options reported in this filing?

The filing shows 12,500 shares underlying an employee stock option directly held by Morgen Eric’s spouse, reported as indirect ownership. The nature of ownership is labeled “By Spouse,” clarifying that these derivative securities are associated with the spouse rather than held directly.

Does this BioAge Labs (BIOA) Form 4 show buying or selling of common stock?

The Form 4 reports stock option grants categorized as acquisitions, not open-market buying or selling of common stock. Both transactions use code “A” for grant or award, indicating new derivative awards rather than purchases or sales of existing BioAge Labs shares.